A Study on The Proportion/Hospital Based Prevalance of Non-Alcoholic Fatty Liver Disease (NAFLD) in Diagnosed Cases of Polycystic Ovarian Syndrome (PCOS) Seen in A Tertiary Care Centre of Bihar

1.1. Aims To evaluate the proportion/hospital-based prevalence of non-alcoholic fatty liver disease in diagnosed cases of polycystic ovarian syndrome and to evaluate and compare the various relevant biochemical parameters and their derangements in cases of PCOS with NAFLD and cases of PCOS without NAFLD. 1.2. Methods This was a cross-sectional observational study which included 86 patients of PCOS in the age group of 15-35 years between December 2020 to January 2021.A detailed history was obtained from cases. Patients were screened for clinical signs of hyperandrogenism. Transabdominal USG was undertaken to detect polycystic ovaries and for detecting steatosis and its grade. Also, shear wave elastography was performed for assessing the liver fibrosis and the reading noted. Anthropometric measurement and Hormone assay were done. All the data were analysed using SPSS package for windows. 1.3. Results Out of 86 PCOS patients, 36 patients had NAFLD (41.87%) and 50 patients had no NAFLD (58.13%). Overweight patients have 27 times more risk of developing NAFLD condition (OR 27.429, 95% CI 5.69-132.27), whereas Obese patients have 36 times risk (OR 36.00, 95% CI 5.65-229.29) of developing NAFLD condition. Higher BMI is associated with developing of NAFLD. Waist/Hip ratio of ≥0.8 was also noted to have 89 times more risk of developing NAFLD (OR 89, 95% CI 17.767-448.341). Higher testosterone levels were associated with 1.35 times more risk of developing NAFLD (OR 1.352, 95% CI 0.552-3.311). Higher OGTT values were associated with 1.292 times more risk of developing NAFLD. Deranged lipid profile was found to confer more risk of developing NAFLD. 1.4. Conclusion NAFLD is commonly found in women with PCOS, and may be an early sign of metabolic syndrome. Patients with PCOS should be screened for NAFLD as early interventions can be an important measure to reduce the risk of progression to advanced liver disease.